| Mr Ryan Lee Welch, LPN | |
|
13190 South Outer 40 Rd, Chesterfield, MO 63017-5917 | |
| (314) 434-3330 | |
| Not Available |
| Full Name | Mr Ryan Lee Welch |
|---|---|
| Gender | Male |
| Speciality | Licensed Practical Nurse |
| Location | 13190 South Outer 40 Rd, Chesterfield, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154990067 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 2014043634 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Ryan Lee Welch, LPN 13190 South Outer 40 Rd, Chesterfield, MO 63017-5917 Ph: (314) 434-3330 | Mr Ryan Lee Welch, LPN 13190 South Outer 40 Rd, Chesterfield, MO 63017-5917 Ph: (314) 434-3330 |
News Archive
Merck, known as MSD outside the United States and Canada, and AiCuris today announced that they have entered into an exclusive worldwide licensing agreement for AiCuris' novel portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of HCMV infection in transplant recipients.
Excess iron in the body, if left unchecked, can form toxic deposits in major organs leading to serious conditions including heart failure, diabetes, liver cirrhosis, arthritis, and even infertility. Iron overload can be a consequence of a genetically mutated gene known as hereditary hemochromatosis, or a consequence of red blood cell transfusions, required as life saving treatments, for patients with diseases such as thalassemia.
In living systems, complex nano- and microscale structures perform a host of physical and biological functions. While two-dimensional patterns can be recreated fairly well with techniques like microlithography, three-dimensional structures represent a big challenge.
Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days.
New research has found that the availability of a portable eight-slice computed tomography (CT) scanner in an emergency room can significantly increase the number of stroke victims who receive a potentially life-saving treatment.
› Verified 8 days ago
Earniecia Mae Bradley, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 100 Chesterfield Business Pkwy Ste 200, Chesterfield, MO 63005 Phone: 314-485-9575 | |
Mackenzie Schneider, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 14561 N Outer 40 Rd, Chesterfield, MO 63017 Phone: 636-235-8587 |